Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 4/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25832767 | 1.00 | LPL (0.39) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL14816525 | 0.90 | LPL (0.38) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL1477757 | 0.90 | LPL (0.38) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL29977632 | 0.90 | LPL (0.38) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL1646761 | 0.87 | LPL (0.44) | LPLLIPGJAK2BTKP2RX7 | |
| SCHEMBL24457822 | 0.85 | CYP3A4 (0.35) | LPLLIPGJAK2BTKMAPK1 | |
| SCHEMBL31531403 | 0.85 | LPL (0.35) | LPLLIPGJAK2BTK | |
| SCHEMBL1397050 | 0.85 | LPL (0.35) | LPLLIPGJAK2BTKEGFR | |
| SCHEMBL21067074 | 0.85 | CYP3A4 (0.35) | LPLLIPGJAK2BTKMAPK1 | |
| SCHEMBL30935317 | 0.85 | CYP3A4 (0.35) | LPLLIPGJAK2BTKMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | LPL 1508/4885LIPG 2089/4885JAK2 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.